SBRA
SBRA
Sabra Health Care REIT, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $211.9M ▲ | $66.91M ▲ | $27.23M ▲ | 12.85% ▲ | $0.11 ▲ | $107.98M ▲ |
| Q3-2025 | $190.04M ▲ | $60.83M ▲ | $22.54M ▼ | 11.86% ▼ | $0.09 ▼ | $100.36M ▼ |
| Q2-2025 | $189.15M ▲ | $56.1M ▼ | $65.54M ▲ | 34.65% ▲ | $0.28 ▲ | $137.17M ▲ |
| Q1-2025 | $183.54M ▲ | $56.22M ▲ | $40.3M ▼ | 21.96% ▼ | $0.17 ▼ | $111.31M ▼ |
| Q4-2024 | $182.35M | $55.22M | $46.7M | 25.61% | $0.2 | $125.19M |
What's going well?
Revenue is up sharply, and profits are growing even faster. The company is keeping expenses in check, and earnings per share are rising.
What's concerning?
Gross margins slipped a bit, and interest costs remain a big drag on profits. Share dilution means each share represents a slightly smaller piece of the company.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $71.54M ▼ | $5.49B ▼ | $2.67B ▼ | $2.82B ▼ |
| Q3-2025 | $200.6M ▲ | $5.56B ▲ | $2.74B ▲ | $2.82B ▲ |
| Q2-2025 | $95.17M ▲ | $5.33B ▲ | $2.62B ▲ | $2.71B ▲ |
| Q1-2025 | $22.65M ▼ | $5.23B ▼ | $2.53B ▼ | $2.7B ▼ |
| Q4-2024 | $60.47M | $5.3B | $2.56B | $2.74B |
What's financially strong about this company?
The company has solid asset quality with almost no goodwill, and it reduced its debt load significantly this quarter. Equity remains strong, and there are no hidden liabilities.
What are the financial risks or weaknesses?
Liquidity is in crisis—current assets cover only a fraction of near-term bills, and cash reserves are low. Negative retained earnings show a history of losses, and working capital is under pressure.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $27.23M ▲ | $87.43M ▼ | $-116.55M ▲ | $-100.89M ▼ | $-129.38M ▼ | $87.43M ▼ |
| Q3-2025 | $22.52M ▼ | $99.96M ▲ | $-199.84M ▼ | $206.17M ▲ | $105.87M ▲ | $99.96M ▲ |
| Q2-2025 | $65.54M ▲ | $80.96M ▲ | $-45.13M ▼ | $36.73M ▲ | $72.75M ▲ | $80.96M ▲ |
| Q1-2025 | $40.3M ▼ | $80.26M ▲ | $-16.44M ▼ | $-101.24M ▼ | $-37.44M ▼ | $80.26M ▲ |
| Q4-2024 | $46.7M | $79.97M | $18.56M | $-100.96M | $-2.64M | $79.97M |
What's strong about this company's cash flow?
The company generates steady cash from its core business, easily covering dividends. It is reducing debt and still producing more cash than reported profits, showing high-quality earnings.
What are the cash flow concerns?
Cash flow from operations is declining, and the company had a big drop in cash this quarter. Ongoing need to issue new shares and the lack of capital investment may not be sustainable long-term.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Health Care Resident Service Ancillary Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Sabra Health Care REIT, Inc.'s financial evolution and strategic trajectory over the past five years.
Sabra shows a clear financial and operational turnaround, with rising revenue, much-improved profitability, and strong, steady cash flow that comfortably supports dividends. Its portfolio is diversified across essential healthcare and senior living segments that benefit from long-term demographic demand. Management brings deep operator experience, which underpins strong tenant relationships and a more hands-on SHOP strategy, while practical innovation in technology and sustainability enhances property performance and competitive positioning.
Key concerns center on the balance sheet and operating leverage: liquidity ratios have weakened sharply as short-term debt and other current liabilities have surged, raising refinancing and near-term funding risk. Retained earnings have historically been negative and were reset through capital actions rather than built steadily through profits. Overhead costs are rising faster than revenue, and capital expenditures are very low, potentially limiting organic growth in the asset base. The business also faces external risks from healthcare regulation, reimbursement changes, labor pressures, and interest rate movements.
The overall picture points to a company with improving earnings power and strong cash generation, operating in a sector with favorable long-term demand drivers but meaningful structural and financial risks. Future performance will likely hinge on how well Sabra manages its debt structure and liquidity, executes on expanding and optimizing its SHOP and behavioral health platforms, and continues to validate the returns from its technology and sustainability initiatives. If these elements are balanced carefully, Sabra could sustain its recent momentum, but its reliance on capital markets and the complexity of the healthcare ecosystem remain important constraints and watchpoints.
About Sabra Health Care REIT, Inc.
https://www.sabrahealth.comAs of March 31, 2022, Sabra's investment portfolio included 416 real estate properties held for investment.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $211.9M ▲ | $66.91M ▲ | $27.23M ▲ | 12.85% ▲ | $0.11 ▲ | $107.98M ▲ |
| Q3-2025 | $190.04M ▲ | $60.83M ▲ | $22.54M ▼ | 11.86% ▼ | $0.09 ▼ | $100.36M ▼ |
| Q2-2025 | $189.15M ▲ | $56.1M ▼ | $65.54M ▲ | 34.65% ▲ | $0.28 ▲ | $137.17M ▲ |
| Q1-2025 | $183.54M ▲ | $56.22M ▲ | $40.3M ▼ | 21.96% ▼ | $0.17 ▼ | $111.31M ▼ |
| Q4-2024 | $182.35M | $55.22M | $46.7M | 25.61% | $0.2 | $125.19M |
What's going well?
Revenue is up sharply, and profits are growing even faster. The company is keeping expenses in check, and earnings per share are rising.
What's concerning?
Gross margins slipped a bit, and interest costs remain a big drag on profits. Share dilution means each share represents a slightly smaller piece of the company.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $71.54M ▼ | $5.49B ▼ | $2.67B ▼ | $2.82B ▼ |
| Q3-2025 | $200.6M ▲ | $5.56B ▲ | $2.74B ▲ | $2.82B ▲ |
| Q2-2025 | $95.17M ▲ | $5.33B ▲ | $2.62B ▲ | $2.71B ▲ |
| Q1-2025 | $22.65M ▼ | $5.23B ▼ | $2.53B ▼ | $2.7B ▼ |
| Q4-2024 | $60.47M | $5.3B | $2.56B | $2.74B |
What's financially strong about this company?
The company has solid asset quality with almost no goodwill, and it reduced its debt load significantly this quarter. Equity remains strong, and there are no hidden liabilities.
What are the financial risks or weaknesses?
Liquidity is in crisis—current assets cover only a fraction of near-term bills, and cash reserves are low. Negative retained earnings show a history of losses, and working capital is under pressure.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $27.23M ▲ | $87.43M ▼ | $-116.55M ▲ | $-100.89M ▼ | $-129.38M ▼ | $87.43M ▼ |
| Q3-2025 | $22.52M ▼ | $99.96M ▲ | $-199.84M ▼ | $206.17M ▲ | $105.87M ▲ | $99.96M ▲ |
| Q2-2025 | $65.54M ▲ | $80.96M ▲ | $-45.13M ▼ | $36.73M ▲ | $72.75M ▲ | $80.96M ▲ |
| Q1-2025 | $40.3M ▼ | $80.26M ▲ | $-16.44M ▼ | $-101.24M ▼ | $-37.44M ▼ | $80.26M ▲ |
| Q4-2024 | $46.7M | $79.97M | $18.56M | $-100.96M | $-2.64M | $79.97M |
What's strong about this company's cash flow?
The company generates steady cash from its core business, easily covering dividends. It is reducing debt and still producing more cash than reported profits, showing high-quality earnings.
What are the cash flow concerns?
Cash flow from operations is declining, and the company had a big drop in cash this quarter. Ongoing need to issue new shares and the lack of capital investment may not be sustainable long-term.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Health Care Resident Service Ancillary Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Sabra Health Care REIT, Inc.'s financial evolution and strategic trajectory over the past five years.
Sabra shows a clear financial and operational turnaround, with rising revenue, much-improved profitability, and strong, steady cash flow that comfortably supports dividends. Its portfolio is diversified across essential healthcare and senior living segments that benefit from long-term demographic demand. Management brings deep operator experience, which underpins strong tenant relationships and a more hands-on SHOP strategy, while practical innovation in technology and sustainability enhances property performance and competitive positioning.
Key concerns center on the balance sheet and operating leverage: liquidity ratios have weakened sharply as short-term debt and other current liabilities have surged, raising refinancing and near-term funding risk. Retained earnings have historically been negative and were reset through capital actions rather than built steadily through profits. Overhead costs are rising faster than revenue, and capital expenditures are very low, potentially limiting organic growth in the asset base. The business also faces external risks from healthcare regulation, reimbursement changes, labor pressures, and interest rate movements.
The overall picture points to a company with improving earnings power and strong cash generation, operating in a sector with favorable long-term demand drivers but meaningful structural and financial risks. Future performance will likely hinge on how well Sabra manages its debt structure and liquidity, executes on expanding and optimizing its SHOP and behavioral health platforms, and continues to validate the returns from its technology and sustainability initiatives. If these elements are balanced carefully, Sabra could sustain its recent momentum, but its reliance on capital markets and the complexity of the healthcare ecosystem remain important constraints and watchpoints.

CEO
Richard K. Matros
Compensation Summary
(Year 2024)
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-11-16 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 249
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
UBS
Neutral
Citigroup
Buy
Citizens
Market Outperform
Cantor Fitzgerald
Neutral
Truist Securities
Hold
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:38.39M
Value:$788.99M
VANGUARD GROUP INC
Shares:35.43M
Value:$728.09M
BLACKROCK INC.
Shares:34.39M
Value:$706.65M
Summary
Showing Top 3 of 600

